MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from sale ofcommon stock,...$25,765K Proceeds from exercise ofwarrants$1,527K Net cash provided byfinancing activities$27,284K Effect of exchange ratechanges on cash and cash...$51K Canceled cashflow$8K Net increase(decrease) in cash and cash...$4,600K Canceled cashflow$22,735K Payment of tax liabilityfor vested...$8K Loss on issuance ofwarrant liabilities-$30,962K Stock-based compensation$1,664K Transaction costs allocatedto warrant...$1,407K Accounts payable$1,330K Loss onextinguishment of warrant...-$614K Depreciation andamortization$90K Accrued expenses andother liabilities$17K Net cash used inoperating activities-$22,735K Canceled cashflow$36,084K Net loss-$33,560K Change in fair value ofwarrant liabilities-$24,441K Prepaid expenses andother assets$792K Operating lease, net-$26K
Cash Flow
source: myfinsight.com

Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech, Inc. (MBRX)